Cargando…
Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients
BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecede...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655870/ https://www.ncbi.nlm.nih.gov/pubmed/29065921 http://dx.doi.org/10.1186/s13024-017-0217-5 |
_version_ | 1783273619768475648 |
---|---|
author | Konrad, Csaba Kawamata, Hibiki Bredvik, Kirsten G. Arreguin, Andrea J. Cajamarca, Steven A. Hupf, Jonathan C. Ravits, John M. Miller, Timothy M. Maragakis, Nicholas J. Hales, Chadwick M. Glass, Jonathan D. Gross, Steven Mitsumoto, Hiroshi Manfredi, Giovanni |
author_facet | Konrad, Csaba Kawamata, Hibiki Bredvik, Kirsten G. Arreguin, Andrea J. Cajamarca, Steven A. Hupf, Jonathan C. Ravits, John M. Miller, Timothy M. Maragakis, Nicholas J. Hales, Chadwick M. Glass, Jonathan D. Gross, Steven Mitsumoto, Hiroshi Manfredi, Giovanni |
author_sort | Konrad, Csaba |
collection | PubMed |
description | BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecedented size of fibroblasts from patients with sporadic ALS (sALS, n = 171), primary lateral sclerosis (PLS, n = 34), ALS/PLS with C9orf72 mutations (n = 13), and healthy controls (n = 91). In search for novel ALS classifiers, we performed extensive studies of fibroblast bioenergetics, including mitochondrial membrane potential, respiration, glycolysis, and ATP content. Next, we developed a machine learning approach to determine whether fibroblast bioenergetic features could be used to stratify patients. RESULTS: Compared to controls, sALS and PLS fibroblasts had higher average mitochondrial membrane potential, respiration, and glycolysis, suggesting that they were in a hypermetabolic state. Only membrane potential was elevated in C9Orf72 lines. ATP steady state levels did not correlate with respiration and glycolysis in sALS and PLS lines. Based on bioenergetic profiles, a support vector machine (SVM) was trained to classify sALS and PLS with 99% specificity and 70% sensitivity. CONCLUSIONS: sALS, PLS, and C9Orf72 fibroblasts share hypermetabolic features, while presenting differences of bioenergetics. The absence of correlation between energy metabolism activation and ATP levels in sALS and PLS fibroblasts suggests that in these cells hypermetabolism is a mechanism to adapt to energy dissipation. Results from SVM support the use of metabolic characteristics of ALS fibroblasts and multivariate analysis to develop classifiers for patient stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13024-017-0217-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5655870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56558702017-10-31 Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients Konrad, Csaba Kawamata, Hibiki Bredvik, Kirsten G. Arreguin, Andrea J. Cajamarca, Steven A. Hupf, Jonathan C. Ravits, John M. Miller, Timothy M. Maragakis, Nicholas J. Hales, Chadwick M. Glass, Jonathan D. Gross, Steven Mitsumoto, Hiroshi Manfredi, Giovanni Mol Neurodegener Research Article BACKGROUND: The objective of this study was to investigate cellular bioenergetics in primary skin fibroblasts derived from patients with amyotrophic lateral sclerosis (ALS) and to determine if they can be used as classifiers for patient stratification. METHODS: We assembled a collection of unprecedented size of fibroblasts from patients with sporadic ALS (sALS, n = 171), primary lateral sclerosis (PLS, n = 34), ALS/PLS with C9orf72 mutations (n = 13), and healthy controls (n = 91). In search for novel ALS classifiers, we performed extensive studies of fibroblast bioenergetics, including mitochondrial membrane potential, respiration, glycolysis, and ATP content. Next, we developed a machine learning approach to determine whether fibroblast bioenergetic features could be used to stratify patients. RESULTS: Compared to controls, sALS and PLS fibroblasts had higher average mitochondrial membrane potential, respiration, and glycolysis, suggesting that they were in a hypermetabolic state. Only membrane potential was elevated in C9Orf72 lines. ATP steady state levels did not correlate with respiration and glycolysis in sALS and PLS lines. Based on bioenergetic profiles, a support vector machine (SVM) was trained to classify sALS and PLS with 99% specificity and 70% sensitivity. CONCLUSIONS: sALS, PLS, and C9Orf72 fibroblasts share hypermetabolic features, while presenting differences of bioenergetics. The absence of correlation between energy metabolism activation and ATP levels in sALS and PLS fibroblasts suggests that in these cells hypermetabolism is a mechanism to adapt to energy dissipation. Results from SVM support the use of metabolic characteristics of ALS fibroblasts and multivariate analysis to develop classifiers for patient stratification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13024-017-0217-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-10-24 /pmc/articles/PMC5655870/ /pubmed/29065921 http://dx.doi.org/10.1186/s13024-017-0217-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Konrad, Csaba Kawamata, Hibiki Bredvik, Kirsten G. Arreguin, Andrea J. Cajamarca, Steven A. Hupf, Jonathan C. Ravits, John M. Miller, Timothy M. Maragakis, Nicholas J. Hales, Chadwick M. Glass, Jonathan D. Gross, Steven Mitsumoto, Hiroshi Manfredi, Giovanni Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title_full | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title_fullStr | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title_full_unstemmed | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title_short | Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
title_sort | fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655870/ https://www.ncbi.nlm.nih.gov/pubmed/29065921 http://dx.doi.org/10.1186/s13024-017-0217-5 |
work_keys_str_mv | AT konradcsaba fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT kawamatahibiki fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT bredvikkirsteng fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT arreguinandreaj fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT cajamarcastevena fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT hupfjonathanc fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT ravitsjohnm fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT millertimothym fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT maragakisnicholasj fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT haleschadwickm fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT glassjonathand fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT grosssteven fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT mitsumotohiroshi fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients AT manfredigiovanni fibroblastbioenergeticstoclassifyamyotrophiclateralsclerosispatients |